Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00321
|
|||||
| Drug Name |
Uridine
|
|||||
| Synonyms |
1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 1-beta-D-ribofuranosylpyrimidine-2,4(1H,3H)-dione; AI3-52690; C9H12N2O6; CHEBI:16704; DRTQHJPVMGBUCF-XVFCMESISA-N; EINECS 200-407-5; MLS000069625; SMR000058222; UNII-WHI7HQ7H85; Uracil riboside; Uracil-1-beta-d-ribofuranoside; Urd; Uridin; WHI7HQ7H85; b-Uridine; beta-Uridine; d-uridine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Depression [ICD11:6A8Z] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H12N2O6
|
|||||
| Canonical SMILES |
C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O
|
|||||
| InChI |
InChI=1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6-,7-,8-/m1/s1
|
|||||
| InChIKey |
DRTQHJPVMGBUCF-XVFCMESISA-N
|
|||||
| CAS Number |
CAS 322-35-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 244.2 | Topological Polar Surface Area | 119 | ||
| Heavy Atom Count | 17 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
-2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103313732
,103852268
,104310914
,117358157
,117613647
,118048883
,12109174
,123059964
,124525105
,124799625
,124882993
,126523145
,14710325
,14847540
,15221017
,24900434
,24900638
,24900640
,26702452
,26715956
,26754144
,29225043
,3134852
,3275
,3593
,3718411
,46167442
,46391419
,46504323
,48095962
,49833656
,50059626
,56459453
,57323128
,584045
,77021584
,7891023
,81044517
,81092927
,8139953
,8144667
,8153756
,825827
,85164984
,85230753
,87577750
,88835504
,92298506
,99226784
,99438033
|
|||||
| ChEBI ID |
ChEBI:16704
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | CNT1 | Transporter Info | Concentrative nucleoside transporter 1 | Substrate | [2] | |
| CNT2 | Transporter Info | Concentrative nucleoside transporter 2 | Substrate | [3] | ||
| References | ||||||
| 1 | Uridine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Electrophysiological recordings of CNT1 (SLC28A1) activity on Nanions SURFE2R N1. | |||||
| 3 | Transport of ribavirin across the rat and human placental barrier: Roles of nucleoside and ATP-binding cassette drug efflux transporters. Biochem Pharmacol. 2019 May;163:60-70. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.